Search Results - Bengt Hoepken

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis

    Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with... by Martin Rudwaleit, Pedro M. Machado, Vanessa Taieb, Natasha de Peyrecave, Bengt Hoepken, Lianne S. Gensler

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

    Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol by Walter P. Maksymowych, Thomas Kumke, Simone E. Auteri, Bengt Hoepken, Lars Bauer, Martin Rudwaleit

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis

    Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axia... by Xenofon Baraliakos, Martin Rudwaleit, Pedro M Machado, Bengt Hoepken, Lars Bauer, Rachel Tham, Thomas Kumke, Mindy Kim

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

    Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status by Atul Deodhar, Martin Rudwaleit, Bengt Hoepken, Lars Bauer, Lianne Gensler, Walter Maksymowych, Thomas Kumke, Mindy Kim, Simone Emanuele Auteri

    Published 2024-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study

    Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study... by Philip C. Robinson, Walter P. Maksymowych, Lianne S. Gensler, Stephen Hall, Martin Rudwaleit, Bengt Hoepken, Lars Bauer, Thomas Kumke, Mindy Kim, Natasha dePeyrecave, Atul Deodhar

    Published 2022-09-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

    Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd s... by Robert Landewé, Désirée van der Heijde, Atul Deodhar, Martin Rudwaleit, Lianne S Gensler, Walter P Maksymowych, Bengt Hoepken, Lars Bauer, Thomas Kumke, Mindy Kim, Simone Emanuele Auteri

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

    Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE by Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, Lianne S. Gensler

    Published 2020-06-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study

    Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the... by Irene E. van der Horst-Bruinsma, Rianne E. van Bentum, Frank D. Verbraak, Atul Deodhar, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Karen Thomas, Lars Bauer, Martin Rudwaleit

    Published 2021-03-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

    The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW by Martin Rudwaleit, James T Rosenbaum, Irene van der Horst-Bruinsma, Maria Misterska-Skora, Rianne van Bentum, Frank D Verbraak, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Brenda VanLunen, Lars Bauer

    Published 2020-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: